Os therapies receives patent notice of allowance from u.s. patent & trademark office covering commercial manufacturing of ost-her2

New york--(business wire)--os therapies, inc. (nyse-a: ostx), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a notice of allowance from the united states patent & trademark office (uspto) that a patent will be issued covering the manufacturing methods required for the ost-her2 commercial product. the uspto granted a patent term adjustment of 572 days, providing market exclusivity for the os.
OST Ratings Summary
OST Quant Ranking